DeepMind's drug-spinoff lands $5 billion to turn its AI into actual medicine
Original headline: Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials — techcrunch.com
More in AI and machine learning news
Isomorphic Labs, the AI drug-discovery company spun out of Google's DeepMind, has raised a massive $5 billion in a Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and major existing backers like Alphabet's venture arms. The company builds on DeepMind's AlphaFold breakthrough to design novel drugs using AI simulation models, and has already reported positive preclinical results in oncology and immunology while partnering with pharma giants Eli Lilly, Novartis, and Johnson & Johnson.
This fresh capital, following a $2.1 billion round just months ago, will fuel the expansion of its AI drug-design engine into more therapeutic areas and help push its most promising candidates toward clinical trials. The funding reflects immense investor confidence in using advanced AI to radically accelerate and improve the traditional drug discovery pipeline, a field historically plagued by high costs and failure rates. The bet is that Isomorphic's technology can turn protein-structure predictions into tangible, life-saving treatments.
Read the original at techcrunch.com
Satirical commentary on real tech news, summarised with AI. Read the original source for the facts. How ZeroDaily works
